Drugs / SHEN26
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05504746 | Aug → Dec 2022 | — | Shenzhen Kexing Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05676073 | Dec 2022 | COVID-19 | Shenzhen Kexing Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05908071 | May 2023 → May 2024 | COVID-19 | Shenzhen Kexing Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHEN26 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05504746 ↗ |
| Known as | ATV014 | “SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor” PMID 39863888 ↗ Jan 2025 |
| Action | Inhibit | “novel RdRp inhibitor SHEN26” PMID 38662639 ↗ Apr 2024 |
| Modality | Small molecule | “novel oral small-molecule antiviral drug” PMID 39863888 ↗ Jan 2025 |
| Route | Oral | “Participants will receive SHEN26 capsule(s) orally for a single dose.” NCT05504746 ↗ |